Suppr超能文献

体外培养的人源和鼠源肿瘤细胞中各种叶酸类似物的总多聚谷氨酰化及细胞毒性的类似差异。

Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro.

作者信息

Samuels L L, Moccio D M, Sirotnak F M

出版信息

Cancer Res. 1985 Apr;45(4):1488-95.

PMID:3978616
Abstract

Four folate analogues, methotrexate, aminopterin, 10-deazaminopterin, and 10-ethyl-10-deazaaminopterin were assessed for their ability to be metabolized to poly-gamma-glutamyl derivatives in three tumor lines which vary in their sensitivity to these agents. Cytotoxicity of the four analogues against the murine L1210 leukemia and the human Manca B cell leukemia, as determined by a 3-h clonogenic assay, showed aminopterin and the two 10-deazaaminopterin compounds to be approximately equivalent for each cell type and were 3- to 10- (L1210) and 7- to 14-fold (Manca) more potent than methotrexate. In murine Sarcoma 180 cells, 10-ethyl-10-deazaaminopterin and aminopterin were similarly potent but were 5- to 10-fold more potent than 10-deazaaminopterin and 40- to 80-fold more potent than methotrexate. These results could be explained in part by the differences in transport properties and substrate activities for polyglutamylation for each analogue in these cell types. Initial rates of polyglutamate accumulation of the four analogues, which were determined under conditions of comparable rates of drug entry into the three tumor cell lines, were 7- to 18-fold less than drug entry rates. In L1210 and Sarcoma 180 cells, the relative rates of polyglutamylation were in the order aminopterin greater than 10-ethyl-10-deazaaminopterin greater than methotrexate greater than 10-deazaaminopterin. In contrast, the relative rates of polyglutamylation in Manca cells were in the order 10-ethyl-10-deazaaminopterin approximately equal to aminopterin greater than 10-deazaaminopterin greater than methotrexate, suggesting that folylpolyglutamyl synthetase may have varying substrate preferences in different cell types. The maximum relative extents of total polyglutamate accumulation in L1210 cells were 85 to 95% of the total drug at 24 h. In Manca cells, the maximum polyglutamate accumulation was also 85 to 95%, but this was obtained by 6 h. However, in Sarcoma 180 cells, only aminopterin polyglutamates reached a similar maximum percentage of accumulation, while lower relative polyglutamate levels were achieved with the other analogues. Accumulation of individual polyglutamates in each cell line was similar for all analogues except aminopterin. For methotrexate and the two 10-deazaaminopterins, accumulation occurred mainly as the tetraglutamate or as higher polyglutamates. Aminopterin was accumulated mainly as the diglutamate, particularly in Manca cells where 70% of total drug was in the diglutamate form within the first 3 h and remained the predominant form for 24 h.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

评估了四种叶酸类似物,即甲氨蝶呤、氨基蝶呤、10-脱氮氨基蝶呤和10-乙基-10-脱氮氨基蝶呤,在三种对这些药物敏感性不同的肿瘤细胞系中代谢为多聚γ-谷氨酰衍生物的能力。通过3小时克隆形成试验测定,这四种类似物对小鼠L1210白血病细胞和人曼卡B细胞白血病细胞的细胞毒性显示,氨基蝶呤和两种10-脱氮氨基蝶呤化合物对每种细胞类型的活性大致相当,且比甲氨蝶呤强3至10倍(对L1210细胞)和7至14倍(对曼卡细胞)。在小鼠肉瘤180细胞中,10-乙基-10-脱氮氨基蝶呤和氨基蝶呤同样有效,但比10-脱氮氨基蝶呤强5至10倍,比甲氨蝶呤强40至80倍。这些结果部分可以通过这些细胞类型中每种类似物的转运特性和多聚谷氨酰化底物活性的差异来解释。在药物进入三种肿瘤细胞系的速率相当的条件下测定的四种类似物的多聚谷氨酸积累初始速率,比药物进入速率低7至18倍。在L1210和肉瘤180细胞中,多聚谷氨酰化的相对速率顺序为氨基蝶呤>10-乙基-10-脱氮氨基蝶呤>甲氨蝶呤>10-脱氮氨基蝶呤。相反,曼卡细胞中多聚谷氨酰化的相对速率顺序为10-乙基-10-脱氮氨基蝶呤≈氨基蝶呤>10-脱氮氨基蝶呤>甲氨蝶呤,这表明叶酸多聚谷氨酰合成酶在不同细胞类型中可能有不同的底物偏好。L1210细胞中24小时时总多聚谷氨酸积累的最大相对程度为总药物的85%至95%。在曼卡细胞中,多聚谷氨酸的最大积累也为85%至95%,但在6小时时达到。然而,在肉瘤180细胞中,只有氨基蝶呤的多聚谷氨酸达到类似的最大积累百分比,而其他类似物的多聚谷氨酸相对水平较低。除氨基蝶呤外,每种细胞系中各类似物的单个多聚谷氨酸积累情况相似。对于甲氨蝶呤和两种10-脱氮氨基蝶呤,积累主要以四聚谷氨酸或更高的多聚谷氨酸形式出现。氨基蝶呤主要以二聚谷氨酸形式积累,特别是在曼卡细胞中,在前3小时内总药物的70%以二聚谷氨酸形式存在,并在24小时内保持主要形式。(摘要截断于400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验